Literature DB >> 2843682

Synthesis of functional human immunodeficiency virus tat protein in baculovirus as determined by a cell-cell fusion assay.

K T Jeang1, P R Shank, A B Rabson, A Kumar.   

Abstract

The human immunodeficiency virus tat protein is a strong trans-activator of the expression of mRNAs originating from the viral long terminal repeat. We have expressed the first 72 amino acids (coding exon 1) of this protein in eucaryotic Spodoptera frugiperda SF9 cells by using a baculovirus vector, Autographa californica nuclear polyhedrosis virus. We show that the baculovirus vector stably produced the 72-amino-acid form of the tat protein but was unable to stably synthesize a larger 101-amino-acid full-length version of the same polypeptide. The 72-amino-acid tat protein, when introduced into mammalian fibroblasts by using a cell-cell fusion technique, functionally trans-activated the expression of the human immunodeficiency virus long terminal repeat.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843682      PMCID: PMC253536          DOI: 10.1128/JVI.62.10.3874-3878.1988

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

Review 2.  Molecular organization of the AIDS retrovirus.

Authors:  A B Rabson; M A Martin
Journal:  Cell       Date:  1985-03       Impact factor: 41.582

3.  The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat.

Authors:  C A Rosen; J G Sodroski; W A Haseltine
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

4.  Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III.

Authors:  J Sodroski; R Patarca; C Rosen; F Wong-Staal; W Haseltine
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

5.  Post-transcriptional regulation accounts for the trans-activation of the human T-lymphotropic virus type III.

Authors:  C A Rosen; J G Sodroski; W C Goh; A I Dayton; J Lippke; W A Haseltine
Journal:  Nature       Date:  1986 Feb 13-19       Impact factor: 49.962

6.  Transactivation induced by human T-lymphotropic virus type III (HTLV III) maps to a viral sequence encoding 58 amino acids and lacks tissue specificity.

Authors:  L J Seigel; L Ratner; S F Josephs; D Derse; M B Feinberg; G R Reyes; S J O'Brien; F Wong-Staal
Journal:  Virology       Date:  1986-01-15       Impact factor: 3.616

Review 7.  A pathogenic retrovirus (HTLV-III) linked to AIDS.

Authors:  S Broder; R C Gallo
Journal:  N Engl J Med       Date:  1984-11-15       Impact factor: 91.245

8.  Modification and secretion of human interleukin 2 produced in insect cells by a baculovirus expression vector.

Authors:  G E Smith; G Ju; B L Ericson; J Moschera; H W Lahm; R Chizzonite; M D Summers
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

9.  Production of human beta interferon in insect cells infected with a baculovirus expression vector.

Authors:  G E Smith; M D Summers; M J Fraser
Journal:  Mol Cell Biol       Date:  1983-12       Impact factor: 4.272

10.  Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).

Authors:  S K Arya; C Guo; S F Josephs; F Wong-Staal
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

View more
  11 in total

1.  Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.

Authors:  C A Bohan; F Kashanchi; B Ensoli; L Buonaguro; K A Boris-Lawrie; J N Brady
Journal:  Gene Expr       Date:  1992

Review 2.  Expression of eukaryotic genes in insect cultures.

Authors:  M J Fraser
Journal:  In Vitro Cell Dev Biol       Date:  1989-03

3.  Sequential steps in Tat trans-activation of HIV-1 mediated through cellular DNA, RNA, and protein binding factors.

Authors:  A Gatignol; M Duarte; L Daviet; Y N Chang; K T Jeang
Journal:  Gene Expr       Date:  1996

4.  The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity.

Authors:  J Leonard; C Parrott; A J Buckler-White; W Turner; E K Ross; M A Martin; A B Rabson
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

5.  The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner.

Authors:  Dimiter G Demirov; Jan M Orenstein; Eric O Freed
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Transcriptional activation of homologous viral long terminal repeats by the human immunodeficiency virus type 1 or the human T-cell leukemia virus type I tat proteins occurs in the absence of de novo protein synthesis.

Authors:  K T Jeang; P R Shank; A Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

7.  Complementation of murine cells for human immunodeficiency virus envelope/CD4-mediated fusion in human/murine heterokaryons.

Authors:  T Dragic; P Charneau; F Clavel; M Alizon
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

8.  Identification of cellular proteins that bind to the human immunodeficiency virus type 1 trans-activation-responsive TAR element RNA.

Authors:  A Gatignol; A Kumar; A Rabson; K T Jeang
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

9.  Adeno-associated virus Rep protein inhibits human immunodeficiency virus type 1 production in human cells.

Authors:  B A Antoni; A B Rabson; I L Miller; J P Trempe; N Chejanovsky; B J Carter
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

10.  Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat.

Authors:  E J Duh; W J Maury; T M Folks; A S Fauci; A B Rabson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.